Rationale: The success of cardiac stem cell therapies is limited by low cell retention, due at least in part to washout via coronary veins. Objective: We sought to counter the efflux of transplanted cells by rendering them magnetically responsive and imposing an external magnetic field on the heart during and immediately after injection. Methods and Results: Cardiosphere-derived cells (CDCs) were labeled with superparamagnetic microspheres (SPMs). In vitro studies revealed that cell viability and function were minimally affected by SPM labeling. SPM-labeled rat CDCs were injected intramyocardially, with and without a superimposed magnet. With magnetic targeting, cells were visibly attracted toward the magnet and accumulated around the ischemic zone. In contrast, the majority of nontargeted cells washed out immediately after injection. Fluorescence imaging revealed more retention of transplanted cells in the heart, and less migration into other organs, in the magnetically targeted group. Quantitative PCR confirmed that magnetic targeting enhanced cell retention (at 24 hours) and engraftment (at 3 weeks) in the recipient hearts by Ϸ3-fold compared to nontargeted cells. Morphometric analysis revealed maximal attenuation of left ventricular remodeling, and echocardiography showed the greatest functional improvement, in the magnetic targeting group. Histologically, more engrafted cells were evident with magnetic targeting, but there was no incremental inflammation. Conclusions: Magnetic targeting enhances cell retention, engraftment and functional benefit. This novel method to improve cell therapy outcomes offers the potential for rapid translation into clinical applications. (Circ Res. 2010;106:1570-1581.)
S tem cell transplantation is a promising therapeutic strategy for acute or chronic ischemic cardiomyopathy. 1 Low cell retention and engraftment are major obstacles to achieving a significant functional benefit irrespective of the cell type or model used. 2, 3 Acute (Յ24-hour) cell retention is normally less than 10%, regardless of the delivery route. 3 Initial studies highlighted apoptosis as the culprit underlying low engraftment, 4, 5 but recent work has shown that venous drainage and the contraction of a beating heart account for significant loss of transplanted cells. 6, 7 As short-term cell retention is a prerequisite for long-term cell engraftment and functional improvement, translatable methods to attenuate cell loss are highly desirable. Magnetic targeting represents a noninvasive approach to coax therapeutic agents (eg, drugs, cells) into desired regions. 8 In the cardiovascular arena, previous work has concentrated on endothelial cell-related therapies, using magnetic targeting to improve cell homing to grafts or stents. 9 -14 Moreover, previous studies have evaluated only short-term cell retention, not long-term engraftment or functional benefits. 9 -14 Here, we examine myocardial rather than endothelial targeting, and quantify long-term cardiac engraftment and function after intramyocardial injection of iron-labeled cardiosphere-derived cells (CDCs) subjected to an external magnetic attractor.
Effects of SPM Labeling on CDC Properties
In vitro toxicity experiments were performed 24 hours after SPM labeling. Cell viability was assessed by Trypan Blue exclusion. Apoptosis and necrosis were assessed by flow cytometry (7AAD and Annexin-V stain). 15 Methods used to assess cell proliferation and attachment are described in Detailed Methods. Percentages of cells that expressed the antigens c-kit, CD31, CD34 and CD90 were assessed by flow cytometry. 15 The apoptotic/necrotic effects of SPM labeling were examined by TUNEL staining. 19 H 2 O 2 -treated cells and nontreated cells were routinely included as positive and negative controls, respectively. Reactive oxygen species generation was measured by 2 commercially available kits following manufacturers' protocols.
In Vitro Cell Capture Experiments
SPM-labeled CDCs (500:1 SPM:cell ratio) were resuspended in PBS (1 million cells/mL) in a 15 mL conical tube. A 1.3 Tesla magnet was applied directly to the outside tube wall or 1 cm away from the tube for 20 seconds. Cell condensation was assessed visually. To better simulate the contracting and turbulent environment of myocardium, the same magnet was mounted on the outside wall of a cell suspension tube which was rotated at 60 RPM. After 24 hours, cell condensation by magnetic capturing was visually examined.
Cell Injection and Magnetic Targeting
Animal care was in accordance to Institutional Animal Care and Use Committee guidelines. Female WKY (nϭ88 total) rats underwent left thoracotomy under general anesthesia, and myocardial infarction (MI) was produced by permanent ligation of the left anterior descending coronary artery. The animals were subjected to intramyocardial injections with a 29-gauge needle at 4 points in the infarct border zone, with one of the following randomly assigned conditions: (1) Fe-CDCϩmagnet group: injection of 1 million SPMlabeled cells in 100 L of PBS with a 1.3 Tesla magnet applied above the apex during the injection and for 10 minutes after injection; (2) Fe-CDC group: injection of 1 million SPM-labeled cells in 100 L of PBS without magnet application; (3) CDC group: injection of 1 million nonlabeled cells in 100 L of PBS with magnet applied above the apex during the injection and for another 10 minutes after injection; and (4) control group: injection of 100 L of PBS without cells. A SPM control group was subsequently added: injection of 5ϫ10 8 SPM beads (no cells) in 100 L of PBS with magnet applied. A video recorder was attached to the surgical microscope to capture videos during cell injection.
Quantification of Engraftment by Real-Time PCR
Male CDCs were injected into female rats, enabling detection of the SRY gene (located on the Y chromosome) as an index of engraftment. Quantitative real-time PCR was performed 24 hours and 3 weeks after cell injection (nϭ6 for each cell-injected group).
Fluorescence Imaging
CDCs were labeled with SPMs that were conjugated with flash-red fluorophores (excitation: 660 nm; emission: 690 nm). Because of its long wavelength, flash-red is superior to dragon-green for imaging purposes. Hearts, lungs and spleens from representative animals from each group were harvested and imaged with the IVIS 200 (Xenogen) system to detect flash-red fluorescence. Hearts were washed with PBS to remove any cells adherent to the epicardium before imaging. Fluorescence signals (photon/s) from a fixed region of interest (ROI) were measured as described. 20
Echocardiography
To assess global cardiac function in 53 rats (Fe-CDCϩmagnet [nϭ12], Fe-CDC [nϭ12], CDC [nϭ11], PBS control [nϭ9], and SPM control [nϭ9]), echocardiography was performed with the Vevo 770 system (Visual Sonics, Toronto, Canada) on day 0 post-MI and 3 weeks post-MI. The left ventricular ejection fraction (LVEF) was measured from the parasternal long-axis view. LVEF was calculated with Visual Sonics V1.3.8 software from 2D long-axis views taken through the infarcted area. Both absolute values and changes from baseline (day 0 post-MI) are reported.
Morphometric and Histology Analysis
Subpopulations of CDCs from each group were virally transduced to express green fluorescent protein (GFP). 17 In these cases, flash-redconjugated SPMs were used to avoid crossover with the fluorescence of GFP. Animals receiving GFP cells and flash-red SPMs were euthanized 3 weeks after injection. Hearts were cryo-sectioned and representative slides from each depth range were selected for immuohistochemistry. Quantitative morphometry analysis was performed as previously described. 21
Statistical Analysis
Results are presented as meansϮSD unless specified otherwise. Statistical significance between baseline and 3 week LVEFs was determined using 2-tailed paired Student t test. All the other comparisons between any 2 groups were performed using 2-tailed unpaired Student t test. Comparison among more than 2 groups was analyzed by One-Way ANOVA followed by Bonferroni post hoc test. Differences were considered statistically significant when PϽ0.05.
Results

SPM Labeling Minimally Affects Cell Viability and Function
CDCs were labeled with Dragon-green fluorescenceconjugated SPM particles by coincubation in culture for 24 hours. Prussian Blue staining and fluorescence microscopy confirmed particle uptake by CDCs ( Figure 1A and 1B). Nonlabeled cells did not exhibit Prussian Blue or Dragongreen fluorescence (insets, Figure 1A and 1B). These labeled cells are hereafter called SPM-labeled CDCs, or Fe-CDCs for short. Flow cytometry revealed an average labeling efficiency of 86.4Ϯ1.2% when a 500:1 SPM:cell ratio was used. The number of TUNEL ϩ apoptotic cells increased with escalating SPM:cell ratio (red cells with white arrowheads, Figure 2A through 2C; Online Figure I ). From the same images, it is also obvious that more SPMs (green color) were taken up by each cell at higher SPM dosages. Figure 2D and 2E shows typical Annexin/7-AAD flow cytometry plots. Further quantification ( Figure 2F ) indicated that SPM labeling induced Ͻ1% increase of apoptotic cells, but the SPM-labeled group had fewer necrotic cells. Given the fact that 500:1 labeling caused minimal cytotoxicity, this dosage was chosen for subsequent in vitro and in vivo experiments. Figure 2G through 2J shows that labeling with SPMs did not affect cell viability, proliferation, adhesion or antigenic phenotype of CDCs. In addition, SPM labeling did not lead to the generation of intracellular reactive oxygen species (Online Figure II ).
Non-standard Abbreviations and Acronyms
External Magnet Captures SPM-Labeled CDCs In Vitro
To investigate the ability of a magnet to capture SPM-labeled CDCs in vitro, CDCs were loaded with 500:1 SPMs and resuspended in a conical tube (Online Figure III, A) . After applying the magnet directly on the outer wall of the tube, CDCs were rapidly attracted toward the magnet and accumulated focally on the adjacent inner wall (Online Figure III, B) .
To gauge the effect of a more remote magnetic field, the magnet was moved 1 cm away from the tube and the capture experiment was repeated. SPM-labeled CDCs were still rapidly attracted toward the magnet and attached focally, albeit with smaller cell condensates (Online Figure III 
Magnetic Targeting Captures Fe-CDCs During Injection and Attenuates Washout Effect
One million CDCs derived from syngeneic male WKY rats were injected intramyocardially into the peri-infarct region of female hearts. White light imaging revealed that the majority of SPM-labeled CDCs (evident from their yellow-brown color) washed out within seconds (Online Movie I), diffusing from the injection site toward the base and then quickly disappearing. This confirms our prior conclusion 6 that initial washout accounts for significant cell loss. In contrast, Fe-CDCs injected with a magnet placed Ϸ1 cm above the cardiac apex moved toward the apex and accumulated around the infarct (Online Movie II). As seen in the movies, more cells are visible after injection in a heart from the Fe-CDCϩmagnet group (A) than in the Fe-CDC group (B). Thus, the external magnetic force was capable of effectively opposing the hydraulic forces that ordinarily drive washout.
Magnetic Targeting Improves Short-Term Retention and Long-Term Engraftment
Six animals from each cell-injected group were euthanized 24 hours after cell injection to assess short-term cell retention. Visual inspection of the excised hearts revealed that the Fe-CDCϩmagnet group ( Figure 3B , red arrow) had more cells around the injection area than did the Fe-CDC group ( Figure 3A) . Likewise, representative fluorescence imaging (FLI) images revealed more flash-red fluorescence in a heart from the Fe-CDCϩmagnet group ( Figure 3F ) than in the Fe-CDC group ( Figure 3C ). To compare off-target migration, lungs and spleens from the same animals were also harvested and imaged. Not surprisingly, red fluorescence signals were detectable in the lungs, but less so in the lungs from the Fe-CDCϩmagnet group ( Figure 3G ) than in those from the Fe-CDC group ( Figure 3D ). Thus, the magnet retains CDCs in the heart that would otherwise travel elsewhere because of venous dispersion. The fluorescence seen in the Fe-CDC spleen ( Figure 3E ) may reflect off-target CDCs, or clearance of SPM particles by spleen macrophages. In either case, such fluorescence is markedly reduced in the Fe-CDCϩmagnet spleen ( Figure 3H ). As a negative control, excised organs from the CDC group (animals injected with nonlabeled cells) were also imaged. No signals were detectable in any organs ( Figure 3I through 3K).
To further assess the numbers of surviving CDCs in the myocardium, quantitative PCR for the male-specific SRY gene was performed. Quantitative PCR results confirmed that magnetic targeting enhanced short-term cell retention in the recipient hearts: the Fe-CDCϩmagnet group exhibited Ϸ3fold greater cell numbers than the Fe-CDC group ( Figure  4A ). Cell retention was indistinguishable in the Fe-CDC group and the CDC group, confirming the lack of an effect of labeling per se. To examine the effect of magnetic targeting on long-term engraftment, subsets of animals in each group were followed for 3 weeks and then euthanized for quantitative PCR and FLI. Consistent with previous findings, 18, 22 PCR results indicated that all 3 groups experienced a huge . Cell counts at days 0, 2, and 6 were equivalent in the 2 groups. I, Adhesion potency of Fe-CDCs (labeled with 500:1 SPMs) compared with that of control CDCs (nϭ3). Attached cell numbers at 30 minutes, 2 hours, and 4 hours were not statistically different in the 2 groups. J, Phenotypic markers c-kit, CD90, CD31, and CD34 from Fe-CDCs (nϭ8) were compared to those from control CDCs (nϭ9). No statistical differences were detected for any of those markers. Figure 4B ). Again, SPM labeling itself did not affect engraftment, as the Fe-CDC group was comparable to the CDC group. The equivalence of the CDC and Fe-CDC groups at 24 hours ( Figure 4A ) and 3 weeks ( Figure 4B ) confirms the idea that SPM labeling does not affect cell proliferation in vivo, assuming the attrition rate of transplanted CDCs is identical in the 2 groups. FLI images showed more flash-red fluorescence in the Fe-CDCϩmagnet group ( Figure 4D ) than in the Fe-CDC group ( Figure 4C ). Fluorescence intensity was Ϸ4-fold greater in the Fe-CDCϩmagnet group (Figure 4E) . At the 3-week time point, fluorescence intensity will reflect the amount of SPMs in the tissue, but not necessarily the number of engrafted CDCs. By this time, transplanted cells may have died, leaving behind their SPMs in the interstitium or in macrophages; alternatively, exocytosis might allow surviving cells to extrude the particles. 18 Given such considerations, the fact that both PCR and FLI give similar values for "engraftment" is remarkable and quite possibly fortuitous. Nevertheless, it is clear that that magnetic targeting increases both short-term (24 hours) and long-term Fe-CDC engraftment (3 weeks) in the injured myocardium.
Magnetically Targeted Cell Delivery Attenuates Left Ventricular Remodeling and Enhances the Therapeutic Benefit of Cell Transplantation
Morphometric analysis 21 of explanted hearts (nϭ5 to 6 from each group) at 3 weeks showed severe LV chamber dilatation and infarct wall thinning in PBS-injected hearts ( Figure 5A) . In contrast, the 3 cell treated groups ( Figure 5B through 5D) exhibited attenuated LV remodeling. The protective effect was greatest in the Fe-CDCϩmagnet group, which had more viable myocardium ( Figure 5E ) and thicker infarcted walls ( Figure 5G ), but smaller scars ( Figure 5F ) and less LV expansion ( Figure 5H ). The Fe-CDC and CDC groups were indistinguishable in these measures, indicative of a similar treatment effect in those 2 groups.
To investigate whether improved cell retention/engraftment translates to enhanced functional benefit, global LVEF was assessed by echocardiography at baseline (Day 0 after MI and cell injection) and 3 weeks later. LVEF at baseline did not differ between treatment groups, indicating a comparable degree of initial injury ( Figure 6A ). Over the 3 weeks after infarction, LVEF declined progressively in the control group (PBS-injected animals) ( Figure 6A ), whereas LVEF improved in all 3 groups receiving CDCs. These results confirm previous data showing that cardiac function can be significantly improved by transplantation of CDCs. 6, 17, 23, 24 Notably, the Fe-CDCϩmagnet group exhibited better cardiac function compared to either the Fe-CDC group or the CDC group ( Figure 6A; PϽ0.01) . The LVEFs in the Fe-CDC and CDC groups were indistinguishable, again demonstrating that SPM loading did not undermine the salutary effects of CDCs. To facilitate comparisons among groups, we calculated the treatment effect, ie, the change in LVEF at 3 weeks relative to baseline, in each group ( Figure 6B ). PBS injection had a negative treatment effect, as the LVEF decreased over time, consistent with previous work. 6, 17, 23 In contrast, the Fe-CDCϩmagnet group exhibited a sizable positive treatment effect, greater than that in either the Fe-CDC or CDC groups. The treatment effect in the Fe-CDC group was no different than that in the CDC group. In addition, injection of SPMs alone (no cells) had no beneficial effects (Online Figure IV) . To further investigate the relationships between long-term cell retention or myocardial viability on one hand, and cardiac function on the other, 3-week LVEFs were plotted individually against percentages of engraftment ( Figure 6C ) or viable myocardium in the risk region ( Figure 6D ) at 3 weeks. Better heart function was clearly associated with higher cell retention rate (R 2 ϭ0.8086) and increased myocardial viability (R 2 ϭ6282) by linear regression analysis. These composite functional results indicate that the improved cell retention and engraftment in the Fe-CDCϩmagnet group indeed translated into superior functional benefit and attenuation of LV remodeling. 
Magnetic Targeting Enhances Cell Engraftment and Does Not Worsen Inflammation
To further characterize engraftment, hearts from representative animals in each group were harvested 3 weeks after injection and cryo-sectioned for immunohistochemistry. Confocal imaging enabled the detection of transplanted cells (GFP; green); macrophages (CD68; red); and all cell nuclei (DAPI; blue). Figure 7A ). To quantify the effects of magnetic targeting on the spatial distribution of transplanted cells, GFP-positive cells from 50 randomly selected fields (4ϫ10 4 m 2 ) were counted and the number of events was plotted against varying cell numbers ( Figure 7F ). Not surprisingly, most of the fields examined were devoid of transplanted cells in all 3 groups. However, the Fe-CDCϩmagnet group had more engraftment area (less "empty" area) compared to the Fe-CDC or CDC group (PϽ0.05). The number of fields with 1 to 3 engrafted cells was indistinguishable among all the 3 groups. Interestingly, the Fe-CDCϩmagnet group had many more fields with 4 to 10 or Ͼ10 engrafted cells than the Fe-CDC or CDC group (PϽ0.001). Thus, magnetic targeting increases engraftment in focally condensed patches rather than homogeneously.
One potential concern regarding SPMs and magnetic targeting is the possibility of an inflammatory response, but we found that the tissue density of CD-68 ϩ macrophages was comparable in all 3 groups ( Figure 7E ). These observations indicate that the presence of SPMs in the host tissue did not cause or worsen inflammation. Notably, at the 3 week time point the majority of GFP-positive cells are SPM-negative; only Ϸ10% of transplanted cells still contained SPMs. A shift of SPMs from the transplanted CDCs to resident macrophages was clearly evident when sections were compared at 24 hours versus 3 weeks (Online Figure V) . These observations are consistent with the concept that Fe-CDCs expel SPMs via exocytosis in vivo, as occurs with other ironlabeled stem cells, [25] [26] [27] followed by endocytosis by macrophages and eventual incorporation into body's iron stores. 28 We have found that CDCs improve cardiac function both by direct regeneration and by indirect mechanisms. 24 To assess whether transplanted Fe-CDCs differentiate, we stained for cardiac (␣-sarcomeric actin) and endothelial (von Willebrand factor) markers. GFP ϩ /␣-sarcomeric actin (SA) ϩ cells were consistently detected ( Figure 8A ), indicating the ability of transplanted cells to differentiate into cardiomyocytes. The Fe-CDCϩmagnet group had more GFP ϩ /␣-SA ϩ and GFP Ϫ /␣-SA ϩ cells than the CDC or Fe-CDC group (Figure 8B and 8C) . The increase in GFP ϩ /␣-SA ϩ cells attests to the creation of new myocardium by direct differentiation, whereas the increase in GFP Ϫ /␣-SA ϩ cells likely reflects indirect mechanisms (recruitment of endogenous regeneration and/or tissue preservation). 21, 24, 29 To further dissect the mechanism of benefit of magnetic targeting, we quantified the magnet-related increment in various cell populations: recipient-derived myocytes, mature donor-derived myocytes, and immature donor-derived myocytes ( Figure  8D ). Binucleation was used to distinguish between mature and immature myocytes 30 ; such myocytes were distinctly longer than mononucleated myocytes, with a typical length: width ratio Ͼ3:1. Direct regeneration (GFP ϩ /␣-SA ϩ cells) contributed 17.7% of the total benefit; of that percentage, an absolute 7.3% was comprised of mature donor-derived myocytes. In relative terms, 41.2% of the total donor-derived myocytes were binucleated. The quantitative data also suggest that SPM labeling has minimal impact on in vivo cardiac differentiation, as the CDC and Fe-CDC groups had similar densities of GFP ϩ /␣-SA ϩ cells ( Figure 8B ). In addition, remnant SPMs in the cytoplasm did not prevent Fe-CDCs from differentiating into a cardiomyocyte phenotype, as SPM/GFP/␣-SA triple positive cells were detected (Online Figure VI ; highlighted with white solid arrowheads). Endothelial differentiation was also confirmed by the presence of GFP ϩ /von Willebrand factor-positive cells (Online Figure VII ).
Discussion
One of the main hurdles for cellular cardiomyoplasty is the low, variable retention of transplanted cells. 6, 7, 31 Many injected cells are lost because of the combination of tissue blood flow (washing out cells) and cardiac contraction (squeezing out cells). 6 Here, we have demonstrated that brief (10 minutes) magnetic attraction successfully attenuates cell loss during injection. Notably, this transient magnetic targeting seemed to have a "butterfly effect" on subsequent cell therapy outcomes: both functional benefit ( Figure 6 ) and long-term cell engraftment (Figure 7) were enhanced. We rationalize these findings as follows (see Figure 8E for a schematic): magnetic targeting improved short-term cell retention ( Figure 4A) , which boosted long-term engraftment ( Figures 4B and 7A) . The enhanced engraftment translated into greater therapeutic benefit ( Figure 6 ) by both indirect (paracrine) and direct regeneration mechanisms, with the former as the dominant factor ( Figure 8D ). We also found that some of the CDCs surviving at 3 weeks appear in multi-cellular clusters ( Figure 7A and 7F) in the Fe-CDCϩmagnet group, which we speculate may reflect a condensation effect of magnetic targeting. Threedimensional multicellular clusters are generally more resistant to hostile environments, such as the infarcted myocardium, providing mechanical and paracrine support to transplanted neighbors. 32, 33 This is the first study to report magnetically targeted cell therapy for enhanced myocardial regeneration. Previous investigations of magnetically targeted cell delivery for cardiovascular applications are limited to endothelial-related cell therapies such as stent endothelialization or vascular repair. 9 -14 In those cases, rheological forces in large-bore vessels are the major obstacle for magnetic targeting to counter. In a myocardial infarction model, venous efflux is potentiated by the squeezing effect of cardiac contraction. We showed that magnetic targeting can offset the forces driving injected cells out of the myocardium, thereby improving cell engraftment. In addition, previous studies limited their investigation to comparisons of acute cell targeting or retention, without examining possible functional benefits of magnetic targeting. We found that higher cell retention indeed translates into higher engraftment and greater functional improvement downstream. Indeed, the quantitative relationship between engraftment and LV function is striking ( Figure 6C ), validating the strategy of boosting cell retention as a means to enhance functional benefit.
The SPMs used in the present studies represent a class of superparamagnetic iron oxides (SPIOs). Food and Drug Administration-approved SPIOs are nontoxic and biocompatible and have been used as MRI contrast agents in human subjects. 28, 34 Consistent with the literature, 9, 10 our in vitro toxicity data confirmed that micron-size SPIOs had a good safety profile, as they did not significantly alter cell viability, proliferation, adhesion, apoptosis, or antigenic phenotype (Figure 2 ). Also, SPM labeling did not undermine Fe-CDC proliferation ( Figure 4A and 4B) or the potential for cardiac and endothelial differentiation (Online Figures VI and VII) in vivo. These findings are consistent with previous characterization of SPIOs in embryonic stem cells. 35 Magnetic targeting did not increase macrophage infiltration ( Figure 7E ), consistent with previous work. 36, 37 The potential for chemical toxicity of parenteral iron has also been well documented. 38 Iron from injected SPMs will eventually be incorporated into the body's own iron stores. The total amount of iron oxide for diagnostic imaging (40 to 200 mg of Fe) is small compared to the total human iron stores (Ϸ3500 mg). The amount needed for magnetically targeted cell therapy will likely be even smaller. For instance, in the ongoing phase I clinical trial CADUCEUS (see www.clinicaltrials.org), we give a maximum of 25 million CDCs to each study subject. Based on the fact that every SPM particle contains 0.5 pg of iron oxides and a 500:1 SPM to cell ratio is used, only 5 mg of Fe would be administered to each patient treated with such a protocol.
We used direct myocardial injection in this study because it is a well-characterized cell delivery method in small animal models. However, less-invasive routes such as intravenous or intracoronary delivery also stand to benefit from magnetic targeting. Such routes of delivery yield even lower cell retention rates than direct myocardial injection. 39, 40 In pondering the translation of our results to a clinical setting, we envision noninvasive exposure to magnetic fields near the heart while cell delivery is performed. The external magnetic field may be generated as simply as by applying a fixed magnet to the patient's chest, although machines that focus and potentially shape the magnetic field may enable more refinement, extending to specific regions within the body (eg, the posterior wall of the heart). 41 Electromagnetic catheters represent another potential means of focused field generation within defined regions of the body.
We conclude that magnetic targeting enhances cell retention, engraftment and functional benefit in a rat myocardial infarction model. Although it describes a new and promising method, the present study has a number of limitations: we have used only a proof-of-concept small animal model; further optimization is needed to find the best magnetic strength and duration for effective targeting; and large-animal data are necessary to advance the process of translation. In addition, rather than optimizing basal cell dosage, we chose a number consistent with various prior studies 6, 21, 42 that had shown functional benefit in small animals. We recognize that the dosages used here may not be readily scalable to the clinical setting. Further dosage optimization would be valuable, both in small-and large-animal models, to inform future clinical studies.
Novelty and Significance
What Is Known?
• When cells are injected into the heart, the retention of injected cells in the tissue is low, potentially restricting the therapeutic benefit of cardiomyoplasty. • Cardiosphere-derived cells (CDCs) improve cardiac function in the injured heart and exhibit multilineage potential. • Although CDCs can engraft and differentiate into cardiomyocytes and vascular cells in the injured heart, most of their therapeutic benefit is attributable to indirect ("paracrine") mechanisms rather than to direct regeneration.
What New Information Does This Article Contribute?
• Loading cardiosphere-derived cells with iron oxide particles renders them susceptible to magnetic attraction but does not interfere with their viability or function. • Brief external magnetic field application as an adjunct to magnetized CDC injection ("magnetic targeting") triples short-term retention as well as long-term engraftment. • Adverse remodeling of the heart is attenuated, viability is enhanced, and ventricular function is greater with magnetic targeting.
• Greater cell retention leads to superior benefits via scaling of previously described mechanisms (paracrine effects plus a minor contribution of direct regeneration).
The success of stem cell therapies for heart disease is limited by low transplanted cell retention in the tissue, due at least in part to washout via coronary veins. We sought to counter the efflux of transplanted cells by rendering them magnetically responsive and imposing an external magnetic field on the heart during and immediately after injection. CDCs were labeled with superparamagnetic microspheres, a process which did not undermine cell viability or function. Labeled rat CDCs were injected into the peri-infarct region in rats undergoing acute myocardial infarction. When a magnet was superimposed on the surgical field to achieve magnetic targeting, cells were visibly attracted toward the magnet and accumulated around the ischemic zone. In contrast, the majority of nontargeted cells washed out immediately after injection. More transplanted cells were retained in the heart, and fewer migrated into other organs, with magnetic targeting; adverse ventricular remodeling was attenuated, and functional improvement was superior. This simple, novel method to improve injected cell retention is readily generalizable and offers the potential for rapid translation to clinical applications.
